Miles Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Miles Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,585	Closed	-$210K	–	191
2019 Q1	$210K	Buy	+2,585	New	+$167K	0.18%	153

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Miles Capital's IONS Position: Q2 2019 in Review

Miles Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2019, closing a stake of 2,585 shares — an estimated $210K sold.

Miles Capital first reported a position in IONS in Q1 2019 and held it in 1 quarter. The position peaked at $210K in Q1 2019. 396 funds tracked by Wall St. Rank hold IONS as of Q2 2019.

Miles Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Miles Capital sold 2,585 Ionis Pharmaceuticals shares in Q2 2019, an estimated $210K.
Miles Capital first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Miles Capital's Ionis Pharmaceuticals position peaked at $210K in Q1 2019.
396 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2019.

Based on Miles Capital's 13F filing for Q2 2019, filed 13 Aug 2019.